A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
Public ClinicalTrials.gov record NCT03052205. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
Study identification
- NCT ID
- NCT03052205
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Idera Pharmaceuticals, Inc.
- Industry
- Enrollment
- 54 participants
Conditions and interventions
Conditions
Interventions
- IMO-2125 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 8, 2017
- Primary completion
- Jul 23, 2019
- Completion
- Oct 3, 2019
- Last update posted
- Feb 10, 2020
2017 – 2019
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Scottsdale Healthcare Hospitals DBA Honor Health | Scottsdale | Arizona | 85258 | — |
| The University of Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| University of California San Francisco (UCSF) | San Francisco | California | 94143 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| The Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| St. Luke's Hospital | Easton | Pennsylvania | 18045 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03052205, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 10, 2020 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03052205 live on ClinicalTrials.gov.